Sanofi's Lantus Insulin Pen Is in Short Supply as Demand Climbs

Some people with diabetes are struggling to fill a common insulin prescription: Sanofi’s Lantus SoloStar pen is in short supply, and patients say they have had to search multiple pharmacies.

The affected product is the Lantus SoloStar pen containing 3 millilitres of insulin glargine, a long-acting insulin. A Sanofi spokesperson attributed the constraint to increased demand “driven by broader market dynamics” and described the situation as temporary, saying supply should improve “over the coming weeks.”

What long-acting insulin does

Insulin glargine is a basal insulin, and its role differs from the mealtime insulins many patients also use.

The body produces insulin continuously at a low level to control the glucose the liver releases between meals and overnight, separately from the surges accompanying food. Basal insulin replicates that background supply.

Glargine is engineered to precipitate at the injection site and dissolve gradually, producing relatively flat absorption over about 24 hours from a single daily dose.

The consequence for supply is that this is not a medication with room for interruption. Someone with type 1 diabetes without basal insulin develops rising glucose within hours and risks diabetic ketoacidosis, which is a medical emergency.

Is it an official shortage?

Not formally. The product is not currently classified as an FDA shortage, even though patients report real difficulty obtaining it.

The discrepancy reflects how shortage status is determined. It generally depends on the manufacturer reporting a supply disruption and on assessment of national availability — so a product being manufactured normally but distributed unevenly, with regional gaps, may not meet the definition while being genuinely unobtainable in a given pharmacy.

Formal designation matters practically. It triggers mitigation measures, permits certain regulatory flexibilities, and appears on databases pharmacists consult — so its absence leaves patients and pharmacies without the coordination that follows a declared shortage.

The market backdrop

Reporting points to broader shifts in the insulin-pen market, with some other pens leaving the market — a backdrop that concentrates demand on remaining products.

Insulin has undergone considerable commercial disruption in recent years. Price caps and pricing reforms changed the economics substantially, and manufacturers have discontinued products and altered portfolios in response.

Each discontinuation shifts patients onto alternatives. When several occur across a market, demand concentrates on fewer products faster than manufacturing plans anticipated — and insulin production cannot be scaled quickly, since it is a biologic requiring fermentation, purification and fill-finish capacity that takes years to add.

Why substitution is not straightforward

Different basal insulins are not interchangeable unit for unit. They differ in duration, in how flat the profile is, and in how they behave at different doses.

Switching generally requires dose adjustment and closer glucose monitoring for a period, and getting it wrong risks hypoglycaemia in one direction or hyperglycaemia in the other.

Device familiarity matters too. Patients learn a particular pen, and an unfamiliar device introduces error at a moment when they are already adjusting to a different insulin.

What patients can do

Insulin is not a medication anyone should ration or abruptly stop.

If your usual Lantus pen is unavailable, contact your pharmacy about availability and timing, and talk to your prescriber about a suitable alternative long-acting insulin if the wait is a problem.

Why insulin supply is structurally fragile

Episodes like this recur, and the reasons lie in how the insulin market is built rather than in any single manufacturer’s difficulties.

Three companies supply the overwhelming majority of the world’s insulin. That concentration arose because insulin is a biologic requiring substantial manufacturing investment, and because the market has been dominated by the same firms for decades — entry is expensive and margins on older products are thin.

Biosimilar insulins exist and have not fragmented the market the way generics do for small molecules. Producing them requires the same biologic capacity, approval demands more evidence than a generic, and physician and patient familiarity with established brands slows substitution.

The consequence is that a disruption at one manufacturer has few places to go. Demand shifts to the remaining two, who are running their own capacity against their own forecasts and cannot absorb an unexpected increment quickly.

Insulin is also on the WHO essential medicines list and is needed daily and indefinitely by tens of millions of people. A supply chain that thin, for a product with that profile, is a recognised vulnerability — and one that no market participant has an individual incentive to fix.

Do not switch insulins on your own — dosing can differ. General information, not medical advice.